Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11562437 | 0.92 | FNTA (0.45) | L3MBTL1SLC6A4SLC6A3SLC6A2CNR2 | |
| SCHEMBL11565132 | 0.90 | L3MBTL1 (0.43) | L3MBTL1SLC6A4SLC6A3SLC6A2BRD4 | |
| SCHEMBL11598022 | 0.87 | L3MBTL1 (0.44) | L3MBTL1FFAR2CNR2KMT2AALDH1A1 | |
| SCHEMBL11596977 | 0.87 | CYP1A2 (0.46) | L3MBTL1CNR2KMT2AALDH1A1 | |
| SCHEMBL4013605 | 0.86 | L3MBTL1 (0.46) | L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL11595553 | 0.86 | CYP1A2 (0.45) | L3MBTL1CNR2KMT2AALDH1A1 | |
| SCHEMBL4776154 | 0.82 | L3MBTL1 (0.45) | L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL1564938 | 0.82 | CYP1A2 (0.50) | KMT2AALDH1A1 | |
| SCHEMBL8881032 | 0.82 | ESR1 (0.54) | SLC6A3SLC6A2KMT2AALDH1A1 | |
| SCHEMBL85762 | 0.82 | BRD4 (0.41) | L3MBTL1BRD4HDAC4HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1980563-A1 | Procedure for the preparation of methyl (+)-(S)-Alpha-(O-chlorophenyl)-6,7-dihydrothieno-[3,2-C]pyridine-5(4H) acetate | BATTULA, Srinivasa Reddy (IN) | 2008-10-15 | — | — | EP | claimed |
| EP-4720034-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | Zydus Lifesciences Limited (IN) | 2026-04-08 | — | — | EP | disclosed |
| US-20250223307-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4582420-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Global Health Drug Discovery Institute (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250197379-A1 | NOVEL RAS INHIBITORS | SJP BIOTEC GMBH (CH) | 2025-06-19 | — | — | US | disclosed |
| WO-2024252254-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-12-12 | — | — | WO | disclosed |
| EP-4395897-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2024-07-10 | — | — | EP | disclosed |
| CN-118234715-A | Novel RAS inhibitors | KHR生物技术有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118063438-A | MDM2/MDMX double-target inhibitor compound, prodrug, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024104304-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京华益健康药物研究中心 | 2024-05-23 | — | — | WO | disclosed |
| US-5246929-A | Prophylaxis or treatment of ischemic encephalopathia | TANABE SEIYAKU CO., LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| US-5240938-A | Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring | MERCK & CO., INC. (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0517812-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0441539-A2 | Thiazine (or oxazine) derivatives and preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4882340-A | INHIBITS REFLECTIVE CONTRACTION OF URINARY BLADDER | TANABE SEIYAKU CO., LTD. (JP) | 1989-11-21 | — | — | US | disclosed |
| US-4829067-A | INHIBITORS OF REFLECTIVE CONTRACTION OF BLADDER | TANABE SEIYAKU CO., LTD. (JP) | 1989-05-09 | — | — | US | disclosed |
| EP-0306226-A2 | A benzofuran derivative and processes for preparing the same | Tanabe Seiyaku Co., Ltd. (JP) | 1989-03-08 | — | — | EP | disclosed |
| EP-0270342-A2 | A benzo-furan (or -thiophene) derivative and processes for preparing the same | Tanabe Seiyaku Co., Ltd. (JP) | 1988-06-08 | — | — | EP | disclosed |
| US-4067996-A | HYPOLIPEMIC, HYPOCHOLESTEROLEMIC | SYNTHELABO (FR) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197379-A1 | NOVEL RAS INHIBITORS | KRAS, NRAS, HRAS | L3MBTL1 1509/4885SLC6A4 4627/4885SLC6A3 4722/4885 |
| US-20250223307-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | MDM2, TP53, TP53BP1 | L3MBTL1 2120/4885SLC6A4 4155/4885SLC6A3 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.